MetaCap

Bio-Rad Laboratories (BIO) vs Pacific Biosciences of California (PACB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bio-Rad Laboratories (BIO) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 13.3% versus a loss of 26.6%. Over five years, BIO leads with a -52.2% price change compared with -93.0% for PACB. Bio-Rad Laboratories is the larger company by market cap ($9.65 billion vs $508.9 million), about 19.0 times the size, while Pacific Biosciences of California is growing revenue faster (+3.9% vs +0.7%).

Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -341.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIO+13.32%PACB-26.58%
+35%-10%-54%
Nov 21, 20251 yearNov 20, 2026
BIO-53.79%PACB-93.84%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIO versus PACB key metrics
MetricBIOPACB
Share price$358.90$1.63
Market cap$9.65B$508.95M
1-day change-2.34%-7.39%
YTD return+18.45%-12.83%
1-year return+13.32%-26.58%
5-year return-52.16%-93.01%
P/E ratio (TTM)9.54—
Forward P/E36.23—
EPS (TTM)$37.64$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.58B$160.00M
Revenue growth (YoY)+0.65%+3.89%
Net income (latest FY)$759.90M$-546.38M
Gross margin51.87%28.61%
Operating margin1.83%-346.15%
Net margin29.42%-341.47%
52-week high$396.23$3.44
52-week low$236.73$1.07
Distance from 52-week high-9.42%-52.62%
Analyst consensusholdbuy
Avg. price target upside-0.62%+68.10%
Average volume257.70K13.23M
Shares outstanding21.83M312.24M
Employees7,450485
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Bio-Rad Laboratories is about 19.0 times larger than Pacific Biosciences of California by market value ($9.65B vs $508.95M).
  • BIO has outperformed PACB by 39.9 percentage points over the past year.
  • Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.

About Bio-Rad Laboratories

BIO stock →

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.

Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees

About Pacific Biosciences of California

PACB stock →

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees

BIO vs PACB FAQ

Which is bigger, Bio-Rad Laboratories or Pacific Biosciences of California?

Bio-Rad Laboratories (BIO) is larger, with a market capitalization of $9.65B compared with $508.95M for Pacific Biosciences of California (PACB).

Which stock has performed better over the past year, BIO or PACB?

BIO returned +13.32% over the past 12 months, compared with -26.58% for PACB (price return, excluding dividends). Past performance does not predict future results.

Are Bio-Rad Laboratories and Pacific Biosciences of California in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons